Cabinet Barny advised Neurochlore on the conclusion of an exclusive license agreement with Servier for the development and commercialization of bumetanide in the field of autism in children in Europe.

Cabinet Barny advised Domain Therapeutics on the conclusion of a second licensing and partnership agreement on GPCR biosensor technology with Université de Montréal, the Institute for Research in Immunology and Cancer – Commercialization of Research and McGill University.

Click here for more information.

Cabinet Barny advised Enterome on the conclusion of a collaboration agreement with Bristol-Myers Squibb in the field of Immuno-Oncology, focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules.

Click here for more information.

Cabinet Barny advised Domain Therapeutics on the creation with Medicxi of Mavalon Therapeutics, a company focused on stopping the progression of Parkinson's disease.

Click here for more information.